Overview

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborator:
Genmab